China-based Hangzhou Diagens Biotechnology Co., Ltd. has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange, sponsored solely by Huatai International.
Company and Technology Overview
Diagens Bio is a provider of medical imaging artificial intelligence (AI) solutions. Its in-house developed iMedImage is recognized as the world’s largest general-purpose medical imaging foundation model by parameter scale and the first commercially available cross-modal medical imaging foundation model globally. This advanced model supports 19 medical imaging modalities and covers over 90% of clinical imaging scenarios. It enables multimodal, multitask, and multiscenario AI medical solutions, potentially reducing R&D costs, accelerating time-to-market, and enhancing diagnostic efficiency.
Product and Market Strategy
Built on iMedImage, Diagens has established a comprehensive AI medical imaging solution system that includes foundation models, intelligent medical devices, reagents & consumables, and large model services. Its flagship product, AI AutoVision, is the world’s first AI-driven chromosomal karyotyping diagnostic system. Designated as a Class III medical device by China’s National Medical Products Administration (NMPA), it has fast-track status and its market filing is currently under review after completing clinical trials.
Financial Performance
In 2024, Diagens Bio reported revenues of RMB 70.35 million (USD 9.8 million) and a net loss of RMB 43.38 million (USD 6 million).-Fineline Info & Tech
